Ticarcillin/clavulanate for the treatment of female genital tract infections. Efficacy, safety and comparative microbiology.
In an open study, ticarcillin/clavulanate was used to treat upper genital tract infections in 91 women. The clinical success rate was 92% in outpatient-acquired salpingitis (pelvic inflammatory disease), 50% in salpingitis with tuboovarian abscess, 85% in postpartum endometritis, 87% in endometritis after chorioamnionitis and 90% in postoperative parametritis. The primary adverse reaction was diarrhea, in 10 patients. Among the 129 aerobes isolated, 18 (14%) were beta-lactamase positive, as were 32% (20/63) of the anaerobes.
McGregor
J A
JA
Department of Obstetrics and Gynecology, University of Colorado, Health Science Center, Denver 80262.
D000031:Abortion, Septic / Q000188:drug therapy / Q000382:microbiology; D000328:Adult; D001419:Bacteria / Q000302:isolation & purification; D002481:Cellulitis / Q000188:drug therapy / Q000382:microbiology; D002969:Clavulanic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use; D004716:Endometritis / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy / Q000382:microbiology; D010406:Penicillins / Q000627:therapeutic use*; D011247:Pregnancy; D013982:Ticarcillin / Q000009:adverse effects / Q000627:therapeutic use*; D065093:beta-Lactamase Inhibitors
D002969:Clavulanic Acids; D010406:Penicillins; D065093:beta-Lactamase Inhibitors; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin